Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ceftibuten + xeruborbactam
- Development stage
- Unknown
- Lead developer
- Qpex Biopharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Ceftibuten + xeruborbactam** is an investigational fixed-dose oral combination of ceftibuten, a third-generation oral cephalosporin antibiotic, and xeruborbactam, a cyclic boronic acid beta-lactamase inhibitor delivered as a prodrug. Xeruborbactam inhibits a broad range of beta-lactamases, including serine and metallo-beta-lactamases, restoring and enhancing ceftibuten’s activity against multidrug-resistant Gram-negative pathogens. The combination is in development for oral treatment of complicated urinary tract infections (cUTI), including pyelonephritis, and other infections caused by beta-lactamase-producing bacteria where oral therapy is desirable or required. It is being developed to address antibiotic resistance and enable effective outpatient management of serious Gram-negative infections. Qpex Biopharma is the primary developer[1][2][7][9].
- Brand names
- ORAvance
- Other names
- ceftibuten + xeruborbactam
02
Targets
PBP (Penicillin-binding protein family)β-lactamase
Beyond the preview
Go deeper on ceftibuten + xeruborbactam.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ceftibuten + xeruborbactam.